Fresenius Kabi has announced the availability of Fulvestrant Injection 250mg/5mL prefilled syringe that is stable at room temperature. The product is bioequivalent to Faslodex (AstraZeneca).
The FDA has approved label changes for AstraZeneca‘s Faslodex (fulvestrant) injection. Labeling updates include results and a Kaplan-Meier plot of the final overall survival (OS) analysis from CONFIRM ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
Fresenius Kabi is offering fulvestrant injection in a 250mg per 5mL prefilled syringe. Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, making it ...
(NYSE:AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company ...
Dr. Reddy’s is offering fulvestrant injection, in a dosage strength of 250 mg/5 ml (50 mg/ml) per single-dose syringe. The product is the generic of AstraZeneca’s Faslodex (fulvestrant) injection. The ...
Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication of fulvestrant to include its use with abemaciclib for treatment of certain ...
APPROVAL EXPANDS USE AND OFFERS ADDITIONAL OPTION FOR WOMEN WITH HR+, HER2- METASTATIC BREAST CANCER (WILMINGTON, Del., March 2, 2016) – AstraZeneca today announced that the US Food and Drug ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results